V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10006861 | 10004715 | 1.79 | 69.9 | Neo-adjuvant (N) | 2015-01-25 | 2015-04-19 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 10473522 | VEPEMB |
| 10006862 | 10004716 | 1.61 | 75 | Palliative (P) | 2018-07-18 | 2018-07-25 | REMODLB TRIAL | N | N | 10474818 | R-EPOCH |
| 10006863 | 10004717 | 1.67 | 95.3 | Curative (C) | 2014-07-28 | 2014-08-04 | PCV | 2 | N | 10474833 | ECX |
| 10006864 | 10004719 | null | 63.9 | Disease modification (D) | 2017-10-31 | 2017-11-01 | ECX | N | N | 10474993 | CYTARABINE + FLUDARABINE |
| 10006865 | 10004719 | 1.56 | 91.2 | Curative (C) | 2016-10-20 | 2016-11-23 | FEC | 02 | N | 10474993 | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN |
| 10006866 | 10004719 | null | 86.65 | Palliative (P) | null | 2015-05-08 | Alemtuzumab | N | null | 10474993 | CISPLATIN + GEMCITABINE |
| 10006867 | 10004719 | 1.73 | 61 | Palliative (P) | 2018-05-18 | 2018-07-22 | CETUXIMAB + IRINOTECAN + MDG | 2 | N | 10474993 | EOX |
| 10006868 | 10004720 | null | null | Curative (C) | 2017-04-15 | 2017-04-15 | LEAM | 02 | null | 10475843 | CAPECITABINE + CISPLATIN |
| 10006869 | 10004721 | 1.83 | 79 | Adjuvant (A) | 2014-09-02 | 2014-10-07 | Chlorambucil | N | N | 10476014 | CISPLATIN + GEMCITABINE |
| 10006870 | 10004722 | 1.74 | 82.3 | Palliative (P) | 2015-05-14 | 2015-06-26 | Cape+Cisplatin+Trastuzumab Main | 02 | N | 10476222 | ECARBOX |
| 10006871 | 10004725 | 1.7 | 85 | Palliative (P) | 2017-11-01 | 2017-11-24 | Vemurafenib | N | N | 10476241 | ENZALUTAMIDE |
| 10006872 | 10007394 | 1.58 | 0 | Palliative (P) | 2017-06-06 | 2017-09-22 | Vinorelbine (oral) | N | N | 10476241 | CISPLATIN + FLUOROURACIL |
| 10006873 | 10004726 | null | 74.5 | Palliative (P) | 2017-02-15 | 2017-02-22 | VEDex | N | null | 10477547 | EC |
| 10006874 | 10004727 | 1.66 | 82 | Palliative (P) | 2018-08-06 | 2018-08-07 | Brentuximab | 2 | N | 10477547 | VEPEMB |
| 10006875 | 10004728 | 1.7 | 73.1 | Not known (9) | 2014-11-16 | 2015-01-13 | CHLORAMBUCIL + RITUXIMAB | N | N | 10478078 | CETUXIMAB + IRINOTECAN |
| 10006876 | 10004728 | 1.7 | 73.7 | Adjuvant (A) | 2015-03-07 | 2015-03-10 | Docetaxel + Nintedanib | N | N | 10478078 | CABAZITAXEL |
| 10006877 | 10004728 | 1.5 | null | null | 2017-10-31 | 2017-10-31 | Cisplatin +Fluorouracil (3 wk) | 01 | N | 10478078 | LIPOSOMAL DOXORUBICIN |
| 10006878 | 10004729 | 1.64 | 42.7 | Palliative (P) | 2016-04-11 | 2016-04-15 | FEC + DOCETAXEL + TRASTUZUMAB | N | N | 10478608 | ECX |
| 10006879 | 10004731 | 1.87 | 87.6 | Palliative (P) | 2017-01-25 | 2017-02-25 | DHAP - R | 02 | Y | 10478963 | METHOTREXATE HIGH DOSE |
| 10006880 | 10004732 | 1.7 | 107 | Palliative (P) | 2015-05-01 | 2015-05-01 | BORTEZOMIB + THALIDOMIDE | N | N | 10479023 | NIVOLUMAB |
| 10006881 | 10004733 | null | 84 | Palliative (P) | 2016-02-28 | 2016-02-29 | DOCETAXEL + TRASTUZUMAB | N | N | 10479078 | NIVOLUMAB |
| 10006882 | 10004733 | 1.82 | 86.4 | Curative (C) | 2018-07-19 | 2018-07-31 | Capecitabine + Cisplatin + RT | 2 | Y | 10479078 | GEMCITABINE + OXALIPLATIN + PACLITAXEL |
| 10006883 | 10004734 | 1.77 | 58 | Curative (C) | 2017-11-10 | 2017-11-10 | Docetaxel + Nintedanib | 2 | N | 10479321 | EC |
| 10006884 | 10004735 | 1.62 | 63.6 | Palliative (P) | 2018-03-14 | 2018-03-28 | CISPLATIN + FLUOROURACIL | 2 | N | 10479334 | BORTEZOMIB |
| 10006885 | 10007398 | 1.79 | 85 | Palliative (P) | 2017-05-06 | 2017-05-11 | CABOZANTINIB | 02 | Y | 10479334 | GEFITINIB |
| 10006886 | 10007398 | 1.57 | 78 | Disease modification (D) | null | 2016-11-24 | Capecitabine (21 day) + Irinotecan | N | N | 10479334 | FLUDARABINE |
| 10006887 | 10007398 | 1.67 | 89.5 | Curative (C) | 2017-03-03 | 2017-03-05 | CHLORAMBUCIL + OBINUTUZUMAB | 02 | null | 10479334 | VINCRISTINE |
| 10006888 | 10004736 | 1.7 | 112.8 | Disease modification (D) | 2017-11-16 | 2017-11-30 | CISPLATIN + GEMCITABINE | N | N | 10479591 | CHLORAMBUCIL |
| 10006889 | 10004736 | 1.76 | 71 | Palliative (P) | 2014-12-03 | 2014-12-10 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | N | 10479591 | MITOMYCIN |
| 10006890 | 10004736 | 1.67 | 90 | null | 2014-10-01 | 2014-10-03 | ECF | 02 | N | 10479591 | METHOTREXATE INTRATHECAL |
| 10006891 | 10004739 | 1.72 | 77.7 | Palliative (P) | 2014-08-04 | 2014-11-21 | Melphalan IV High dose | 02 | null | 10479858 | ECX |
| 10006892 | 10004740 | 1.54 | null | Palliative (P) | 2018-10-20 | 2018-11-19 | Carboplatin + Doxorubicin | N | N | 10479928 | VEDEX |
| 10006893 | 10004741 | 1.78 | 83.8 | Palliative (P) | 2018-01-20 | 2018-02-26 | DHAP - R | N | N | 10479928 | CETUXIMAB + IRINOTECAN + MDG |
| 10006894 | 10004742 | 1.76 | null | Curative (C) | 2019-01-09 | 2019-02-06 | Venetoclax | 1 | N | 10479958 | OBINUTUZUMAB |
| 10006895 | 10008538 | 1.78 | null | Curative (C) | 2017-06-14 | 2017-06-27 | IPILIMUMAB + NIVOLUMAB | N | N | 10480034 | METHOTREXATE INTRATHECAL |
| 10006896 | 10007403 | 1.65 | 64.8 | Curative (C) | null | 2018-06-07 | EOX | N | N | 10480034 | CISPLATIN + FLUOROURACIL |
| 10006897 | 10007403 | 1.72 | 70 | Curative (C) | 2017-02-10 | 2017-02-10 | CISPLATIN + FLUOROURACIL | 2 | N | 10480034 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10006898 | 10004744 | 1.72 | 68 | Palliative (P) | 2018-06-15 | 2018-07-02 | Erlotinib | N | N | 10480145 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB |
| 10006899 | 10004745 | 1.88 | null | Palliative (P) | 2017-06-23 | 2017-07-01 | CYCLOPHOSPHAMIDE + FLUDARABINE | null | null | 10480170 | CYTARABINE + RITUXIMAB |
| 10006900 | 10004747 | 1.7 | 76 | Curative (C) | 2014-10-19 | 2014-11-03 | ECX | 2 | N | 10480174 | FCR |
| 10006901 | 10004748 | 1.7 | null | Curative (C) | 2014-06-02 | 2014-07-17 | INCA TRIAL | 02 | null | 10480250 | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN |
| 10006902 | 10004749 | 1.8 | 65 | Palliative (P) | 2017-06-10 | 2017-06-22 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10480320 | TRIFLURIDINE + TIPIRACIL |
| 10006903 | 10004751 | 1.7 | 74.1 | Adjuvant (A) | 2017-11-22 | 2017-11-24 | Bevacizumab+Carbo+Pacliaxel | 2 | N | 10480343 | AFATINIB |
| 10006904 | 10004752 | 1.54 | 71.2 | null | 2017-06-26 | 2017-07-09 | Carbo F | N | N | 10480361 | CAPECITABINE + CARBOPLATIN |
| 10006905 | 10004753 | 1.7 | 55 | Not known (9) | null | 2018-08-20 | PERTUZUMAB + TRASTUZUMAB | N | N | 10480379 | CHOP |
| 10006906 | 10004754 | 1.67 | 70.5 | Curative (C) | 2016-09-27 | 2016-11-14 | Bexarotene | N | N | 10480547 | UKALL2014 |
| 10006907 | 10004754 | 1.6 | 54 | Disease modification (D) | 2019-05-19 | 2019-05-20 | Imatinib 200mg | N | N | 10480547 | IMATINIB |
| 10006908 | 10004756 | 1.84 | 82.8 | Palliative (P) | 2015-08-21 | 2015-08-25 | Trifluridine + Tipiracil | 02 | N | 10480763 | PANITUMUMAB |
| 10006909 | 10004757 | 0 | 59.4 | Curative (C) | 2015-02-18 | 2015-03-20 | Docetaxel + Nintedanib | N | N | 10480769 | ECX |
| 10006910 | 10004758 | 1.75 | 0 | Palliative (P) | 2016-05-02 | 2016-06-11 | Irinotecan | N | Y | 10480824 | AFATINIB |